Obesity and Systemic Oxidative Stress: Clinical Correlates of Oxidative Stress in The Framingham Study

By J. Keaney, Martin G. Larson, Ramachandran S. Vasan, Peter W. F. Wilson, I. Lipinska, D. Corey, J. Massaro, P. Sutherland, J. Vita, Emelia J. Benjamin. Arteriosclerosis, Thrombosis and Vascular Biology, 2003

1,425 citations recorded by the source corpus.

Subfields: Biochemistry, Clinical Biochemistry, Immunology

View Paper: https://www.semanticscholar.org/paper/5b6216784361cb713d144913bd396da342b5ab6d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biochemistry

1. Barry Halliwell
2. M. Whiteman
3. P. Barnes
4. L. Roberts
5. P. Montuschi
6. J. Keaney
7. S. Biswas
8. T. Vogt

In Clinical Biochemistry

1. Barry Halliwell
2. M. Traber
3. M. Whiteman

In Immunology

1. P. Barnes
2. Barry Halliwell
3. M. Whiteman
4. J. Keaney

Citations in the corpus

• Vitamins C and E: Beneficial effects from a mechanistic perspective (2011, background): “Obesity is an inflammatory disease associated with increased F2isoprostanes [159].”
• Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. (2013, background): “[24] Keaney Jr JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al.”
• Inflammation, Oxidative Stress, and Obesity (2011, background): “Another OS marker is the urinary levels of 8-iso Prostaglandin F2α (8-iso PGFα), which are positively related with obesity and insulin resistance [30] and negatively associated with plasma concentration of adiponectin.”
• Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? (2004, result): “This is consistent with the view that lipid peroxidation is an important contributor to cardiovascular disease and can help explain why weight loss and statins decrease cardiovascular events (Roberts et al., 2002; Keaney et al., 2003; Morrow, 2003; Russell et al., 2003; Samuelsson et al., 2003).”
• Reactive Oxygen Species in Cardiovascular Disease (2011, background): “Thus, in the future it may make more sense to measure oxidative stress markers, such as F2-isoprostanes that have been used successfully clinically [45], as a means to target appropriate patients and document appropriate antioxidant efficacy.”
• Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training (2013, neutral): “Obesity is now recognized as a state of chronic, low-grade inflammation and is associated with increased serum markers of inflammation and oxidative stress (196, 345), and MS has been linked with inflammation and oxidative stress (196, 254).”
• Increased oxidative stress in obesity and its impact on metabolic syndrome. (2004, result): “(A) Correlation of plasma TBARS, urinary 8-epi-PGF2α, and plasma adiponectin with BMI and waist circumference.”
• Isoprostanes: markers and mediators of oxidative stress (2004, background): “Cardiovascular diseases Lung diseases Atherosclerosis (92) Asthma (44, 45) Ischemia/reperfusion injury (93, 94) Chronic obstructive pulmonary disease (57, 103) Coronary artery disease (95) Cystic fibrosis (58, 88) Heart failure (56, 96) Interstitial lung disease (104) Renovascular disease (97) Acute”